Veeda Lifesciences partners Mango Sciences to bring AI innovation in clinical trials services

New Delhi: Veeda Lifesciences, a global contract research organization (CRO), has announced an investment in Mango Sciences, a Boston-based healthcare AI and data company.

Through this investment, Veeda intends to leverage AI capabilities to enhance the speed, efficiency, and quality of Clinical Trials services across its expanded global network, enabling more diverse, efficient recruitment and globally representative patient selection.

By leveraging Mango Sciences’ AI-powered Querent™ platform, Veeda will effectively use technology to automate patient identification with precision and expand its reach across Europe.

“Our partnership will transform Veeda into an AI-driven oncology drug development organization, meeting the growing demand for diversity in clinical trials, which is in line with the expectations of regulators and pharmaceutical companies. We will be one of only a few CROs focused in Oncology with access to this proprietary technology” said Dr. Mahesh Bhalgat, Group CEO and Managing Director, Veeda Clinical Research Limited.

This partnership promotes Veeda’s objectives of investing in technology modernization and digital transformation to enhance operational efficiency and quality assurance across its clinical research operations. By deploying the AI-powered Querent™ platform, Veeda will streamline processes, improve data management capabilities, and ensure higher quality standards through broader representation of non-Caucasian populations. This will enhance clinical trial efficiency through advanced data analytics—improving patient matching, trial design, and monitoring while reducing costs and timelines.

Dr. Mohit Misra, Founder & CEO of Mango Sciences, added, “We are integrating Large Language Models (LLMs) and Generative-AI into Querent™ to drive operational efficiencies and improve real-world evidence, ultimately identifying the right drug for the right patient.”

Veeda has strengthened its position as a tech-enabled, AI-driven CRO through strategic investments and the acquisition of Health Data Specialists (Heads) previously. This provides Veeda with access to oncology cohorts in India and Europe and with exclusive access to eligible patient pools. This supports Veeda’s aim to maintain a competitive edge in the CRO sector while delivering services to pharmaceutical and biopharmaceutical clients globally.